
OPKO Health, Inc. – NASDAQ:OPK
OPKO Health stock price today
OPKO Health stock price monthly change
OPKO Health stock price quarterly change
OPKO Health stock price yearly change
OPKO Health key metrics
Market Cap | 1.03B |
Enterprise value | 1.24B |
P/E | -3.15 |
EV/Sales | 1.23 |
EV/EBITDA | -4.57 |
Price/Sales | 1.08 |
Price/Book | 0.69 |
PEG ratio | N/A |
EPS | -0.34 |
Revenue | 799.60M |
EBITDA | -120.67M |
Income | -252.48M |
Revenue Q/Q | -26.89% |
Revenue Y/Y | -12.38% |
Profit margin | -32.7% |
Oper. margin | -24.51% |
Gross margin | 28.7% |
EBIT margin | -24.51% |
EBITDA margin | -15.09% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOPKO Health stock price history
OPKO Health stock forecast
OPKO Health financial statements
Jun 2023 | 265.41M | -19.64M | -7.4% |
---|---|---|---|
Sep 2023 | 178.6M | -84.5M | -47.31% |
Dec 2023 | 181.9M | -66.50M | -36.56% |
Mar 2024 | 173.68M | -81.83M | -47.12% |
Sep 2025 | 205.39M | -44.16M | -21.5% |
---|---|---|---|
Oct 2025 | 190.47M | -44.18M | -23.19% |
Dec 2025 | 198.67M | -40.64M | -20.46% |
Mar 2026 | 940.73M | 2.02M | 0.22% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 2158899000 | 623.55M | 28.88% |
---|---|---|---|
Sep 2023 | 2056700000 | 612.1M | 29.76% |
Dec 2023 | 2011698000 | 622.47M | 30.94% |
Mar 2024 | 1974016000 | 721.20M | 36.54% |
Jun 2023 | -365K | -5.49M | 3.46M |
---|---|---|---|
Sep 2023 | 33.10M | -3.57M | 2.10M |
Dec 2023 | -38.29M | -1.41M | -3.75M |
Mar 2024 | -35.56M | -4.39M | 20.61M |
OPKO Health alternative data
Aug 2023 | 4,196 |
---|---|
Sep 2023 | 4,196 |
Oct 2023 | 4,196 |
Nov 2023 | 4,196 |
Dec 2023 | 4,196 |
Jan 2024 | 4,196 |
Feb 2024 | 4,196 |
Mar 2024 | 3,930 |
Apr 2024 | 3,930 |
May 2024 | 3,930 |
Jun 2024 | 3,930 |
Jul 2024 | 3,930 |
OPKO Health other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 5068025 | 0 |
Feb 2024 | 3000000 | 0 |
Mar 2024 | 2100000 | 0 |
May 2024 | 263997 | 0 |
Sep 2024 | 0 | 0 |
Nov 2024 | 679255 | 0 |
Dec 2024 | 625000 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 125,000 | $1.6 | $199,375 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 125,000 | $1.6 | $199,375 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 500,000 | $1.56 | $781,000 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 500,000 | $1.56 | $781,000 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 199,072 | $1.53 | $305,376 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 199,072 | $1.53 | $305,376 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 100,000 | $1.59 | $159,000 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 100,000 | $1.59 | $159,000 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 100,000 | $1.62 | $162,000 | ||
Purchase | FROST PHILLIP MD ET AL director, 10 perc.. | Common Stock | 100,000 | $1.62 | $162,000 |
Quarter | Transcript |
---|---|
Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 4 Aug 2023 | Q2 2023 Earnings Call Transcript |
How To Pick Top Pharma Stocks: Novo Nordisk And More
OPKO Health: FDA Approval To Save The Company
Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans
OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings
The Great Market Miscalculation: Pfizer's True Value Remains Untapped
OPKO Health's Future After Merck Deal: Bright Or Uncertain
Strong Small-Cap Insider Buys: Q1 2023
Merck & Co., Inc. Is Getting Healthier
Few Options Left For OPKO Health To Heal
-
What's the price of OPKO Health stock today?
One share of OPKO Health stock can currently be purchased for approximately $1.35.
-
When is OPKO Health's next earnings date?
Unfortunately, OPKO Health's (OPK) next earnings date is currently unknown.
-
Does OPKO Health pay dividends?
No, OPKO Health does not pay dividends.
-
How much money does OPKO Health make?
OPKO Health has a market capitalization of 1.03B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14.01% to 863.5M US dollars.
-
What is OPKO Health's stock symbol?
OPKO Health, Inc. is traded on the NASDAQ under the ticker symbol "OPK".
-
What is OPKO Health's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of OPKO Health?
Shares of OPKO Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are OPKO Health's key executives?
OPKO Health's management team includes the following people:
- Dr. Jon R. Cohen Senior Vice President & Director(age: 70, pay: $1,740,000)
- Mr. Adam E. Logal Senior Vice President & Chief Financial Officer(age: 47, pay: $1,110,000)
- Dr. Phillip Frost Ph.D. Chairman & Chief Executive Officer(age: 89, pay: $971,200)
- Dr. Jane H. Hsiao Ph.D., MBA Vice Chairman & Chief Technical Officer(age: 78, pay: $911,200)
- Mr. Steven D. Rubin Executive Vice President of Admin. & Director(age: 65, pay: $821,200)
-
How many employees does OPKO Health have?
As Jul 2024, OPKO Health employs 3,930 workers.
-
When OPKO Health went public?
OPKO Health, Inc. is publicly traded company for more then 29 years since IPO on 2 Nov 1995.
-
What is OPKO Health's official website?
The official website for OPKO Health is opko.com.
-
Where are OPKO Health's headquarters?
OPKO Health is headquartered at 4400 Biscayne Boulevard, Miami, FL.
-
How can i contact OPKO Health?
OPKO Health's mailing address is 4400 Biscayne Boulevard, Miami, FL and company can be reached via phone at +30 55754100.
OPKO Health company profile:

OPKO Health, Inc.
opko.comNASDAQ
3,930
Medical - Diagnostics & Research
Healthcare
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Miami, FL 33137
CIK: 0000944809
ISIN: US68375N1037
CUSIP: 68375N103